查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1872189

循环性肿瘤细胞(CTC) 和癌症干细胞 (CSC) - 全球市场份额和排名、总收入和需求预测（2025-2031 年）

Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
出版日期: | 出版商: QYResearch | 英文 157 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

全球循环性肿瘤细胞(CTC) 和癌症干细胞 (CSC) 市场规模预计在 2024 年达到 211.32 亿美元，预计到 2031 年将增长至 806.75 亿美元，在预测期（2025-2031 年）内复合年增长率为 21.4%。

循环性肿瘤细胞（CTCs）是指从原发肿瘤脱落并经由血液循环扩散的癌细胞，它们从原发肿瘤扩散到其他部位，导致癌症转移。这些细胞存在于癌症患者的周边血液中，检测它们有助于确定转移过程。与其他血球相比，CTCs在血液中极为罕见，因此难以检测。癌症干细胞（CSCs）是指具有正常干细胞所有经典特性的癌细胞。具体而言，它们既具有自我更新的能力，又具有分化为癌组织中所有细胞类型的能力。

由于循环性肿瘤细胞(CTC) 和癌症干细胞 (CSC) 在癌症研究、诊断和治疗开发中发挥重要作用，其市场正在迅速扩张。 CTC 从原发性或转移性肿瘤迁移到血液中，为液态生物检体提供了宝贵的信息，从而实现了非侵入性癌症检测、即时监测和个人化治疗。同时，CSC 是癌细胞的亚群，具有自我更新能力，能够促进肿瘤进展、转移和治疗抗药性。这些细胞类型对于理解癌症生物学和开发标靶治疗至关重要，因此推动了对先进的分离、表征和分析技术的需求。

微流体、免疫磁分离和单细胞分析等检测和富集技术的创新是成长要素。製药和生物技术公司正日益利用循环肿瘤细胞 (CTC) 和癌症干细胞 (CSC) 分析进行药物发现、抗药性机制研究以及个人化癌症治疗方案的发展。人工智慧和基因测序的融合进一步提高了这些平台的准确性和预测价值。随着精准医疗和液态生物检体应用的兴起，CTC 和 CSC 联合市场有望成为癌症诊断和治疗策略制定的基石。

本报告旨在按地区/国家、类型和应用对全球循环性肿瘤细胞(CTC) 和癌症干细胞 (CSC) 市场进行全面分析，重点关注总收入、市场份额和主要企业的排名。

本报告以收益为准，以2024年为基准年，循环性肿瘤细胞（CTC）和癌症干细胞（CSC）的市场规模、估算和预测进行了阐述，并涵盖了2020年至2031年的历史数据和预测数据。透过定量和定性分析，我们帮助读者制定业务和成长策略，评估市场竞争，分析自身在当前市场中的地位，并就循环性肿瘤细胞（CTC）和癌症干细胞（CSC）做出明智的商业决策。

市场区隔

公司

  • Janssen
  • Qiagen
  • Advanced Cell Diagnostics
  • ApoCell
  • Biofluidica
  • Clearbridge Biomedics
  • CytoTrack
  • Celsee
  • Fluxion
  • Gilupi
  • Cynvenio
  • On-chip
  • YZY Bio
  • BioView
  • Fluidigm
  • Ikonisys
  • AdnaGen
  • IVDiagnostics
  • Miltenyi Biotec
  • ScreenCell
  • Silicon Biosystems

按类型分類的细分市场

  • CellSearch
  • 其他的

应用领域

  • 乳癌的诊断和治疗
  • 前列腺癌的诊断和治疗
  • 大肠直肠癌的诊断和治疗
  • 肺癌的诊断和治疗
  • 其他癌症的诊断和治疗

按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太地区
    • 中国
    • 日本
    • 韩国
    • 东南亚
    • 印度
    • 澳洲
    • 亚太其他地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 荷兰
    • 北欧国家
    • 其他欧洲
  • 拉丁美洲
    • 墨西哥
    • 巴西
    • 其他拉丁美洲
  • 中东和非洲
    • 土耳其
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 其他中东和非洲地区

The global market for Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) was estimated to be worth US$ 21132 million in 2024 and is forecast to a readjusted size of US$ 80675 million by 2031 with a CAGR of 21.4% during the forecast period 2025-2031.

Circulating tumor cells (CTCs) are tumor cells that detach from the primary tumor and travel in the bloodstream, spreading from the original tumor to other locations, leading to cancer metastasis. These cells exist in peripheral blood of cancer patients and detection of CTCs can help to determine the process of metastasis. In contrast with other blood cells, the number of CTCs is very rare in blood which makes them difficult to detect. Cancer stem cells (CSCs) are cancer cells that have all the classical properties of normal stem cells. Specifically, they are able to both give rise to more copies of themselves and to give rise to all cell types found in the cancer.

The market for circulating tumor cells (CTCs) and cancer stem cells (CSCs) is expanding rapidly due to their critical role in cancer research, diagnosis, and therapy development. CTCs, which enter the bloodstream from primary or metastatic tumors, provide valuable insights for liquid biopsy, enabling non-invasive cancer detection, real-time monitoring, and treatment personalization. CSCs, on the other hand, are a subpopulation of tumor cells with the ability to self-renew and drive tumor progression, metastasis, and therapy resistance. Together, these cell types are essential for understanding cancer biology and developing targeted therapies, fueling demand for advanced isolation, characterization, and analysis technologies.

Innovation in detection and enrichment technologies-such as microfluidics, immunomagnetic separation, and single-cell analysis-is a major growth driver in this market. Pharmaceutical and biotech companies are increasingly leveraging CTC and CSC analysis for drug discovery, resistance mechanism studies, and personalized oncology approaches. Integration of artificial intelligence and genomic sequencing is further enhancing the accuracy and predictive value of these platforms. With the rise of precision medicine and liquid biopsy applications, the combined CTC and CSC market is expected to become a cornerstone in oncology diagnostics and therapeutic strategy development.

This report aims to provide a comprehensive presentation of the global market for Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs), focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) by region & country, by Type, and by Application.

The Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs).

Market Segmentation

By Company

  • Janssen
  • Qiagen
  • Advanced Cell Diagnostics
  • ApoCell
  • Biofluidica
  • Clearbridge Biomedics
  • CytoTrack
  • Celsee
  • Fluxion
  • Gilupi
  • Cynvenio
  • On-chip
  • YZY Bio
  • BioView
  • Fluidigm
  • Ikonisys
  • AdnaGen
  • IVDiagnostics
  • Miltenyi Biotec
  • ScreenCell
  • Silicon Biosystems

Segment by Type

  • CellSearch
  • Others

Segment by Application

  • Breast Cancer Diagnosis and Treatment
  • Prostate Cancer Diagnosis and Treatment
  • Colorectal Cancer Diagnosis and Treatment
  • Lung Cancer Diagnosis and Treatment
  • Other Cancers Diagnosis and Treatment

By Region

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • Southeast Asia
    • India
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Netherlands
    • Nordic Countries
    • Rest of Europe
  • Latin America
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • UAE
    • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Revenue of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Revenue of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

  • 1.1 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Product Introduction
  • 1.2 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size Forecast (2020-2031)
  • 1.3 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Trends & Drivers
    • 1.3.1 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Industry Trends
    • 1.3.2 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Drivers & Opportunity
    • 1.3.3 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Challenges
    • 1.3.4 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Restraints
  • 1.4 Assumptions and Limitations
  • 1.5 Study Objectives
  • 1.6 Years Considered

2 Competitive Analysis by Company

  • 2.1 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Players Revenue Ranking (2024)
  • 2.2 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Company (2020-2025)
  • 2.3 Key Companies Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Manufacturing Base Distribution and Headquarters
  • 2.4 Key Companies Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Product Offered
  • 2.5 Key Companies Time to Begin Mass Production of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs)
  • 2.6 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Competitive Analysis
    • 2.6.1 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Concentration Rate (2020-2025)
    • 2.6.2 Global 5 and 10 Largest Companies by Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue in 2024
    • 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) as of 2024)
  • 2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

  • 3.1 Introduction by Type
    • 3.1.1 CellSearch
    • 3.1.2 Others
  • 3.2 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Type
    • 3.2.1 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Type (2020 VS 2024 VS 2031)
    • 3.2.2 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value, by Type (2020-2031)
    • 3.2.3 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value, by Type (%) (2020-2031)

4 Segmentation by Application

  • 4.1 Introduction by Application
    • 4.1.1 Breast Cancer Diagnosis and Treatment
    • 4.1.2 Prostate Cancer Diagnosis and Treatment
    • 4.1.3 Colorectal Cancer Diagnosis and Treatment
    • 4.1.4 Lung Cancer Diagnosis and Treatment
    • 4.1.5 Other Cancers Diagnosis and Treatment
  • 4.2 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Application
    • 4.2.1 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Application (2020 VS 2024 VS 2031)
    • 4.2.2 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value, by Application (2020-2031)
    • 4.2.3 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value, by Application (%) (2020-2031)

5 Segmentation by Region

  • 5.1 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Region
    • 5.1.1 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Region: 2020 VS 2024 VS 2031
    • 5.1.2 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Region (2020-2025)
    • 5.1.3 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Region (2026-2031)
    • 5.1.4 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Region (%), (2020-2031)
  • 5.2 North America
    • 5.2.1 North America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value, 2020-2031
    • 5.2.2 North America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Country (%), 2024 VS 2031
  • 5.3 Europe
    • 5.3.1 Europe Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value, 2020-2031
    • 5.3.2 Europe Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Country (%), 2024 VS 2031
  • 5.4 Asia Pacific
    • 5.4.1 Asia Pacific Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value, 2020-2031
    • 5.4.2 Asia Pacific Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Region (%), 2024 VS 2031
  • 5.5 South America
    • 5.5.1 South America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value, 2020-2031
    • 5.5.2 South America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Country (%), 2024 VS 2031
  • 5.6 Middle East & Africa
    • 5.6.1 Middle East & Africa Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value, 2020-2031
    • 5.6.2 Middle East & Africa Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

  • 6.1 Key Countries/Regions Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value Growth Trends, 2020 VS 2024 VS 2031
  • 6.2 Key Countries/Regions Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value, 2020-2031
  • 6.3 United States
    • 6.3.1 United States Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value, 2020-2031
    • 6.3.2 United States Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Type (%), 2024 VS 2031
    • 6.3.3 United States Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Application, 2024 VS 2031
  • 6.4 Europe
    • 6.4.1 Europe Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value, 2020-2031
    • 6.4.2 Europe Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Type (%), 2024 VS 2031
    • 6.4.3 Europe Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Application, 2024 VS 2031
  • 6.5 China
    • 6.5.1 China Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value, 2020-2031
    • 6.5.2 China Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Type (%), 2024 VS 2031
    • 6.5.3 China Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Application, 2024 VS 2031
  • 6.6 Japan
    • 6.6.1 Japan Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value, 2020-2031
    • 6.6.2 Japan Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Type (%), 2024 VS 2031
    • 6.6.3 Japan Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Application, 2024 VS 2031
  • 6.7 South Korea
    • 6.7.1 South Korea Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value, 2020-2031
    • 6.7.2 South Korea Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Type (%), 2024 VS 2031
    • 6.7.3 South Korea Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Application, 2024 VS 2031
  • 6.8 Southeast Asia
    • 6.8.1 Southeast Asia Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value, 2020-2031
    • 6.8.2 Southeast Asia Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Type (%), 2024 VS 2031
    • 6.8.3 Southeast Asia Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Application, 2024 VS 2031
  • 6.9 India
    • 6.9.1 India Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value, 2020-2031
    • 6.9.2 India Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Type (%), 2024 VS 2031
    • 6.9.3 India Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Application, 2024 VS 2031

7 Company Profiles

  • 7.1 Janssen
    • 7.1.1 Janssen Profile
    • 7.1.2 Janssen Main Business
    • 7.1.3 Janssen Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
    • 7.1.4 Janssen Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (US$ Million) & (2020-2025)
    • 7.1.5 Janssen Recent Developments
  • 7.2 Qiagen
    • 7.2.1 Qiagen Profile
    • 7.2.2 Qiagen Main Business
    • 7.2.3 Qiagen Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
    • 7.2.4 Qiagen Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (US$ Million) & (2020-2025)
    • 7.2.5 Qiagen Recent Developments
  • 7.3 Advanced Cell Diagnostics
    • 7.3.1 Advanced Cell Diagnostics Profile
    • 7.3.2 Advanced Cell Diagnostics Main Business
    • 7.3.3 Advanced Cell Diagnostics Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
    • 7.3.4 Advanced Cell Diagnostics Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (US$ Million) & (2020-2025)
    • 7.3.5 Advanced Cell Diagnostics Recent Developments
  • 7.4 ApoCell
    • 7.4.1 ApoCell Profile
    • 7.4.2 ApoCell Main Business
    • 7.4.3 ApoCell Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
    • 7.4.4 ApoCell Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (US$ Million) & (2020-2025)
    • 7.4.5 ApoCell Recent Developments
  • 7.5 Biofluidica
    • 7.5.1 Biofluidica Profile
    • 7.5.2 Biofluidica Main Business
    • 7.5.3 Biofluidica Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
    • 7.5.4 Biofluidica Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (US$ Million) & (2020-2025)
    • 7.5.5 Biofluidica Recent Developments
  • 7.6 Clearbridge Biomedics
    • 7.6.1 Clearbridge Biomedics Profile
    • 7.6.2 Clearbridge Biomedics Main Business
    • 7.6.3 Clearbridge Biomedics Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
    • 7.6.4 Clearbridge Biomedics Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (US$ Million) & (2020-2025)
    • 7.6.5 Clearbridge Biomedics Recent Developments
  • 7.7 CytoTrack
    • 7.7.1 CytoTrack Profile
    • 7.7.2 CytoTrack Main Business
    • 7.7.3 CytoTrack Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
    • 7.7.4 CytoTrack Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (US$ Million) & (2020-2025)
    • 7.7.5 CytoTrack Recent Developments
  • 7.8 Celsee
    • 7.8.1 Celsee Profile
    • 7.8.2 Celsee Main Business
    • 7.8.3 Celsee Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
    • 7.8.4 Celsee Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (US$ Million) & (2020-2025)
    • 7.8.5 Celsee Recent Developments
  • 7.9 Fluxion
    • 7.9.1 Fluxion Profile
    • 7.9.2 Fluxion Main Business
    • 7.9.3 Fluxion Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
    • 7.9.4 Fluxion Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (US$ Million) & (2020-2025)
    • 7.9.5 Fluxion Recent Developments
  • 7.10 Gilupi
    • 7.10.1 Gilupi Profile
    • 7.10.2 Gilupi Main Business
    • 7.10.3 Gilupi Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
    • 7.10.4 Gilupi Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (US$ Million) & (2020-2025)
    • 7.10.5 Gilupi Recent Developments
  • 7.11 Cynvenio
    • 7.11.1 Cynvenio Profile
    • 7.11.2 Cynvenio Main Business
    • 7.11.3 Cynvenio Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
    • 7.11.4 Cynvenio Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (US$ Million) & (2020-2025)
    • 7.11.5 Cynvenio Recent Developments
  • 7.12 On-chip
    • 7.12.1 On-chip Profile
    • 7.12.2 On-chip Main Business
    • 7.12.3 On-chip Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
    • 7.12.4 On-chip Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (US$ Million) & (2020-2025)
    • 7.12.5 On-chip Recent Developments
  • 7.13 YZY Bio
    • 7.13.1 YZY Bio Profile
    • 7.13.2 YZY Bio Main Business
    • 7.13.3 YZY Bio Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
    • 7.13.4 YZY Bio Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (US$ Million) & (2020-2025)
    • 7.13.5 YZY Bio Recent Developments
  • 7.14 BioView
    • 7.14.1 BioView Profile
    • 7.14.2 BioView Main Business
    • 7.14.3 BioView Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
    • 7.14.4 BioView Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (US$ Million) & (2020-2025)
    • 7.14.5 BioView Recent Developments
  • 7.15 Fluidigm
    • 7.15.1 Fluidigm Profile
    • 7.15.2 Fluidigm Main Business
    • 7.15.3 Fluidigm Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
    • 7.15.4 Fluidigm Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (US$ Million) & (2020-2025)
    • 7.15.5 Fluidigm Recent Developments
  • 7.16 Ikonisys
    • 7.16.1 Ikonisys Profile
    • 7.16.2 Ikonisys Main Business
    • 7.16.3 Ikonisys Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
    • 7.16.4 Ikonisys Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (US$ Million) & (2020-2025)
    • 7.16.5 Ikonisys Recent Developments
  • 7.17 AdnaGen
    • 7.17.1 AdnaGen Profile
    • 7.17.2 AdnaGen Main Business
    • 7.17.3 AdnaGen Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
    • 7.17.4 AdnaGen Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (US$ Million) & (2020-2025)
    • 7.17.5 AdnaGen Recent Developments
  • 7.18 IVDiagnostics
    • 7.18.1 IVDiagnostics Profile
    • 7.18.2 IVDiagnostics Main Business
    • 7.18.3 IVDiagnostics Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
    • 7.18.4 IVDiagnostics Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (US$ Million) & (2020-2025)
    • 7.18.5 IVDiagnostics Recent Developments
  • 7.19 Miltenyi Biotec
    • 7.19.1 Miltenyi Biotec Profile
    • 7.19.2 Miltenyi Biotec Main Business
    • 7.19.3 Miltenyi Biotec Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
    • 7.19.4 Miltenyi Biotec Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (US$ Million) & (2020-2025)
    • 7.19.5 Miltenyi Biotec Recent Developments
  • 7.20 ScreenCell
    • 7.20.1 ScreenCell Profile
    • 7.20.2 ScreenCell Main Business
    • 7.20.3 ScreenCell Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
    • 7.20.4 ScreenCell Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (US$ Million) & (2020-2025)
    • 7.20.5 ScreenCell Recent Developments
  • 7.21 Silicon Biosystems
    • 7.21.1 Silicon Biosystems Profile
    • 7.21.2 Silicon Biosystems Main Business
    • 7.21.3 Silicon Biosystems Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
    • 7.21.4 Silicon Biosystems Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (US$ Million) & (2020-2025)
    • 7.21.5 Silicon Biosystems Recent Developments

8 Industry Chain Analysis

  • 8.1 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Industrial Chain
  • 8.2 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Upstream Analysis
    • 8.2.1 Key Raw Materials
    • 8.2.2 Raw Materials Key Suppliers
    • 8.2.3 Manufacturing Cost Structure
  • 8.3 Midstream Analysis
  • 8.4 Downstream Analysis (Customers Analysis)
  • 8.5 Sales Model and Sales Channels
    • 8.5.1 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Model
    • 8.5.2 Sales Channel
    • 8.5.3 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Distributors

9 Research Findings and Conclusion

10 Appendix

  • 10.1 Research Methodology
    • 10.1.1 Methodology/Research Approach
      • 10.1.1.1 Research Programs/Design
      • 10.1.1.2 Market Size Estimation
      • 10.1.1.3 Market Breakdown and Data Triangulation
    • 10.1.2 Data Source
      • 10.1.2.1 Secondary Sources
      • 10.1.2.2 Primary Sources
  • 10.2 Author Details
  • 10.3 Disclaimer

List of Tables

  • Table 1. Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Trends
  • Table 2. Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Drivers & Opportunity
  • Table 3. Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Challenges
  • Table 4. Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Restraints
  • Table 5. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Company (2020-2025) & (US$ Million)
  • Table 6. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue Market Share by Company (2020-2025)
  • Table 7. Key Companies Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Manufacturing Base Distribution and Headquarters
  • Table 8. Key Companies Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Product Type
  • Table 9. Key Companies Time to Begin Mass Production of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs)
  • Table 10. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Companies Market Concentration Ratio (CR5 and HHI)
  • Table 11. Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) as of 2024)
  • Table 12. Mergers & Acquisitions, Expansion Plans
  • Table 13. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 14. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Type (2020-2025) & (US$ Million)
  • Table 15. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Type (2026-2031) & (US$ Million)
  • Table 16. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Market Share in Value by Type (2020-2025)
  • Table 17. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Market Share in Value by Type (2026-2031)
  • Table 18. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 19. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Application (2020-2025) & (US$ Million)
  • Table 20. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Application (2026-2031) & (US$ Million)
  • Table 21. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Market Share in Value by Application (2020-2025)
  • Table 22. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Market Share in Value by Application (2026-2031)
  • Table 23. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
  • Table 24. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Region (2020-2025) & (US$ Million)
  • Table 25. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Region (2026-2031) & (US$ Million)
  • Table 26. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Region (2020-2025) & (%)
  • Table 27. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Region (2026-2031) & (%)
  • Table 28. Key Countries/Regions Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
  • Table 29. Key Countries/Regions Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value, (2020-2025) & (US$ Million)
  • Table 30. Key Countries/Regions Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value, (2026-2031) & (US$ Million)
  • Table 31. Janssen Basic Information List
  • Table 32. Janssen Description and Business Overview
  • Table 33. Janssen Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
  • Table 34. Revenue (US$ Million) in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business of Janssen (2020-2025)
  • Table 35. Janssen Recent Developments
  • Table 36. Qiagen Basic Information List
  • Table 37. Qiagen Description and Business Overview
  • Table 38. Qiagen Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
  • Table 39. Revenue (US$ Million) in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business of Qiagen (2020-2025)
  • Table 40. Qiagen Recent Developments
  • Table 41. Advanced Cell Diagnostics Basic Information List
  • Table 42. Advanced Cell Diagnostics Description and Business Overview
  • Table 43. Advanced Cell Diagnostics Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
  • Table 44. Revenue (US$ Million) in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business of Advanced Cell Diagnostics (2020-2025)
  • Table 45. Advanced Cell Diagnostics Recent Developments
  • Table 46. ApoCell Basic Information List
  • Table 47. ApoCell Description and Business Overview
  • Table 48. ApoCell Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
  • Table 49. Revenue (US$ Million) in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business of ApoCell (2020-2025)
  • Table 50. ApoCell Recent Developments
  • Table 51. Biofluidica Basic Information List
  • Table 52. Biofluidica Description and Business Overview
  • Table 53. Biofluidica Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
  • Table 54. Revenue (US$ Million) in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business of Biofluidica (2020-2025)
  • Table 55. Biofluidica Recent Developments
  • Table 56. Clearbridge Biomedics Basic Information List
  • Table 57. Clearbridge Biomedics Description and Business Overview
  • Table 58. Clearbridge Biomedics Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
  • Table 59. Revenue (US$ Million) in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business of Clearbridge Biomedics (2020-2025)
  • Table 60. Clearbridge Biomedics Recent Developments
  • Table 61. CytoTrack Basic Information List
  • Table 62. CytoTrack Description and Business Overview
  • Table 63. CytoTrack Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
  • Table 64. Revenue (US$ Million) in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business of CytoTrack (2020-2025)
  • Table 65. CytoTrack Recent Developments
  • Table 66. Celsee Basic Information List
  • Table 67. Celsee Description and Business Overview
  • Table 68. Celsee Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
  • Table 69. Revenue (US$ Million) in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business of Celsee (2020-2025)
  • Table 70. Celsee Recent Developments
  • Table 71. Fluxion Basic Information List
  • Table 72. Fluxion Description and Business Overview
  • Table 73. Fluxion Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
  • Table 74. Revenue (US$ Million) in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business of Fluxion (2020-2025)
  • Table 75. Fluxion Recent Developments
  • Table 76. Gilupi Basic Information List
  • Table 77. Gilupi Description and Business Overview
  • Table 78. Gilupi Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
  • Table 79. Revenue (US$ Million) in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business of Gilupi (2020-2025)
  • Table 80. Gilupi Recent Developments
  • Table 81. Cynvenio Basic Information List
  • Table 82. Cynvenio Description and Business Overview
  • Table 83. Cynvenio Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
  • Table 84. Revenue (US$ Million) in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business of Cynvenio (2020-2025)
  • Table 85. Cynvenio Recent Developments
  • Table 86. On-chip Basic Information List
  • Table 87. On-chip Description and Business Overview
  • Table 88. On-chip Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
  • Table 89. Revenue (US$ Million) in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business of On-chip (2020-2025)
  • Table 90. On-chip Recent Developments
  • Table 91. YZY Bio Basic Information List
  • Table 92. YZY Bio Description and Business Overview
  • Table 93. YZY Bio Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
  • Table 94. Revenue (US$ Million) in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business of YZY Bio (2020-2025)
  • Table 95. YZY Bio Recent Developments
  • Table 96. BioView Basic Information List
  • Table 97. BioView Description and Business Overview
  • Table 98. BioView Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
  • Table 99. Revenue (US$ Million) in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business of BioView (2020-2025)
  • Table 100. BioView Recent Developments
  • Table 101. Fluidigm Basic Information List
  • Table 102. Fluidigm Description and Business Overview
  • Table 103. Fluidigm Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
  • Table 104. Revenue (US$ Million) in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business of Fluidigm (2020-2025)
  • Table 105. Fluidigm Recent Developments
  • Table 106. Ikonisys Basic Information List
  • Table 107. Ikonisys Description and Business Overview
  • Table 108. Ikonisys Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
  • Table 109. Revenue (US$ Million) in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business of Ikonisys (2020-2025)
  • Table 110. Ikonisys Recent Developments
  • Table 111. AdnaGen Basic Information List
  • Table 112. AdnaGen Description and Business Overview
  • Table 113. AdnaGen Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
  • Table 114. Revenue (US$ Million) in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business of AdnaGen (2020-2025)
  • Table 115. AdnaGen Recent Developments
  • Table 116. IVDiagnostics Basic Information List
  • Table 117. IVDiagnostics Description and Business Overview
  • Table 118. IVDiagnostics Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
  • Table 119. Revenue (US$ Million) in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business of IVDiagnostics (2020-2025)
  • Table 120. IVDiagnostics Recent Developments
  • Table 121. Miltenyi Biotec Basic Information List
  • Table 122. Miltenyi Biotec Description and Business Overview
  • Table 123. Miltenyi Biotec Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
  • Table 124. Revenue (US$ Million) in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business of Miltenyi Biotec (2020-2025)
  • Table 125. Miltenyi Biotec Recent Developments
  • Table 126. ScreenCell Basic Information List
  • Table 127. ScreenCell Description and Business Overview
  • Table 128. ScreenCell Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
  • Table 129. Revenue (US$ Million) in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business of ScreenCell (2020-2025)
  • Table 130. ScreenCell Recent Developments
  • Table 131. Silicon Biosystems Basic Information List
  • Table 132. Silicon Biosystems Description and Business Overview
  • Table 133. Silicon Biosystems Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
  • Table 134. Revenue (US$ Million) in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business of Silicon Biosystems (2020-2025)
  • Table 135. Silicon Biosystems Recent Developments
  • Table 136. Key Raw Materials Lists
  • Table 137. Raw Materials Key Suppliers Lists
  • Table 138. Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Downstream Customers
  • Table 139. Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Distributors List
  • Table 140. Research Programs/Design for This Report
  • Table 141. Key Data Information from Secondary Sources
  • Table 142. Key Data Information from Primary Sources

List of Figures

  • Figure 1. Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Product Picture
  • Figure 2. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
  • Figure 3. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value (2020-2031) & (US$ Million)
  • Figure 4. Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Report Years Considered
  • Figure 5. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Players Revenue Ranking (2024) & (US$ Million)
  • Figure 6. The 5 and 10 Largest Companies in the World: Market Share by Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue in 2024
  • Figure 7. Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
  • Figure 8. CellSearch Picture
  • Figure 9. Others Picture
  • Figure 10. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 11. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value Market Share by Type, 2024 & 2031
  • Figure 12. Product Picture of Breast Cancer Diagnosis and Treatment
  • Figure 13. Product Picture of Prostate Cancer Diagnosis and Treatment
  • Figure 14. Product Picture of Colorectal Cancer Diagnosis and Treatment
  • Figure 15. Product Picture of Lung Cancer Diagnosis and Treatment
  • Figure 16. Product Picture of Other Cancers Diagnosis and Treatment
  • Figure 17. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 18. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value Market Share by Application, 2024 & 2031
  • Figure 19. North America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value (2020-2031) & (US$ Million)
  • Figure 20. North America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Country (%), 2024 VS 2031
  • Figure 21. Europe Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value, (2020-2031) & (US$ Million)
  • Figure 22. Europe Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Country (%), 2024 VS 2031
  • Figure 23. Asia Pacific Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value, (2020-2031) & (US$ Million)
  • Figure 24. Asia Pacific Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Region (%), 2024 VS 2031
  • Figure 25. South America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value, (2020-2031) & (US$ Million)
  • Figure 26. South America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Country (%), 2024 VS 2031
  • Figure 27. Middle East & Africa Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value, (2020-2031) & (US$ Million)
  • Figure 28. Middle East & Africa Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Country (%), 2024 VS 2031
  • Figure 29. Key Countries/Regions Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value (%), (2020-2031)
  • Figure 30. United States Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value, (2020-2031) & (US$ Million)
  • Figure 31. United States Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Type (%), 2024 VS 2031
  • Figure 32. United States Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Application (%), 2024 VS 2031
  • Figure 33. Europe Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value, (2020-2031) & (US$ Million)
  • Figure 34. Europe Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Type (%), 2024 VS 2031
  • Figure 35. Europe Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Application (%), 2024 VS 2031
  • Figure 36. China Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value, (2020-2031) & (US$ Million)
  • Figure 37. China Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Type (%), 2024 VS 2031
  • Figure 38. China Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Application (%), 2024 VS 2031
  • Figure 39. Japan Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value, (2020-2031) & (US$ Million)
  • Figure 40. Japan Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Type (%), 2024 VS 2031
  • Figure 41. Japan Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Application (%), 2024 VS 2031
  • Figure 42. South Korea Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value, (2020-2031) & (US$ Million)
  • Figure 43. South Korea Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Type (%), 2024 VS 2031
  • Figure 44. South Korea Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Application (%), 2024 VS 2031
  • Figure 45. Southeast Asia Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value, (2020-2031) & (US$ Million)
  • Figure 46. Southeast Asia Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Type (%), 2024 VS 2031
  • Figure 47. Southeast Asia Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Application (%), 2024 VS 2031
  • Figure 48. India Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value, (2020-2031) & (US$ Million)
  • Figure 49. India Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Type (%), 2024 VS 2031
  • Figure 50. India Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Application (%), 2024 VS 2031
  • Figure 51. Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Industrial Chain
  • Figure 52. Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Manufacturing Cost Structure
  • Figure 53. Channels of Distribution (Direct Sales, and Distribution)
  • Figure 54. Bottom-up and Top-down Approaches for This Report
  • Figure 55. Data Triangulation
  • Figure 56. Key Executives Interviewed